title: [Mantle cell lymphoma: management in 2011].
abstract: Mantle cell lymphoma is a rare form of non Hodgkin lymphomas. Diagnosis is made by demonstrating a typical immunophenotype as well as the presence of a translocation between chromosomes 11 and 14 with overexpression of cyclin D1. First line therapy for young patients consists in 3 cycles of "R-CHOP21" alternated with 3 "R-DHAP21" and followed by an autograft conditioned by total body irradiation, cyclophosphamide and aracytine. For patients over 65 years of age, the treatment of choice consists in 8 cycles of "R-CHOP21". Maintenance treatment is under evaluation. Allografting is the only chance of cure in relapsed patients with good performance status. Targeted therapies will improve the prognosis of this disease.
authors.affiliation: Service d'hématologie clinique, Département de médecine interne, CHU Sart-Tilman, Université de Liège, Belgique. cbonnet@ulg.ac.be
authors.forename: C
authors.initials: C
authors.lastname: Bonnet
authors.forename: J
authors.initials: J
authors.lastname: Caers
authors.forename: B
authors.initials: B
authors.lastname: De Prijck
authors.forename: K
authors.initials: K
authors.lastname: Hafraoui
authors.forename: Y
authors.initials: Y
authors.lastname: Beguin
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis* / Q000628:therapy*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant